Market
FDA approval for Novo Nordisk's amycretin by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
Novo Nordisk Shares Surge Over 12% After Amycretin Shows Up to 22% Weight Loss in Early Trial
Jan 24, 2025, 12:00 PM
Novo Nordisk announced positive results from an early-stage Phase 1b/2a trial of its new obesity drug, amycretin. The trial involved 125 participants with overweight or obesity, who achieved up to 22% weight loss over 36 weeks when treated with amycretin. The drug is a novel GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous injection. Following the announcement, Novo Nordisk shares surged more than 12%, their largest increase in a month.
View original story
Similar markets
Merck • 25%
Roche • 25%
Pfizer • 25%
No partnership • 25%
Other rare disease treatment • 25%
No approval • 25%
Haemophilia treatment • 25%
Multiple treatments • 25%
Meets expectations • 25%
Trial cancelled • 25%
Falls short of expectations • 25%
Exceeds expectations • 25%
Heart disease • 25%
Brain disorders • 25%
Kidney disease • 25%
Stroke • 25%